Trials / Completed
CompletedNCT01929044
Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain
A Randomized, Double-blind, Independent 3rd Party Unblind, Active-controlled, Parallel-group, Multi-center Trial, in Contrast With Anisodamine (654-II), 10mg, to Evaluate the Efficacy and Safety of Buscopan® Solution for Injection, 20mg (Intramuscularly) for the Treatment of Acute Gastric or Intestinal Spasm-like Pain
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 299 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to assess the efficacy of Buscopan® (hyoscine butylbromide) in comparison to 654-II (anisodamine)in acute gastric or intestinal spasm-like pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 654-II (anisodamine) | 10mg injection |
| DRUG | Buscopan® (hyoscine butylbromide) | 20mg injection |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2013-08-27
- Last updated
- 2016-03-08
- Results posted
- 2016-03-08
Locations
20 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01929044. Inclusion in this directory is not an endorsement.